Trial Profile
A Phase II, Open-Label, Randomized Study of GDC-0810 Versus Fulvestrant in Postmenopausal Women With Advanced or Metastatic ER+ /HER2- Breast Cancer Resistant to Aromatase Inhibitor Therapy
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Brilanestrant (Primary) ; Fulvestrant
- Indications Advanced breast cancer; Early breast cancer
- Focus Therapeutic Use
- Acronyms HydranGea
- Sponsors Genentech
- 19 Mar 2020 Status changed from active, no longer recruiting to discontinued.
- 03 Apr 2019 Planned End Date changed from 29 Mar 2019 to 28 Mar 2020.
- 03 Apr 2019 Planned primary completion date changed from 29 Mar 2019 to 28 Mar 2020.